Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Empagliflozin - Boehringer Ingelheim/Eli Lilly and Company

Drug Profile

Empagliflozin - Boehringer Ingelheim/Eli Lilly and Company

Alternative Names: BI-10773; Jardiance

Latest Information Update: 10 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Eli Lilly and Company; Medical University of Vienna; Mount Sinai Hospital (Toronto); RWTH Aachen University; University of Oxford; Yale University
  • Class Antihyperglycaemics; Benzhydryl compounds; Cardiovascular therapies; Cyclic ethers; Glucosides; Heart failure therapies; Small molecules
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cardiovascular disorders; Type 2 diabetes mellitus
  • Preregistration Type 1 diabetes mellitus
  • Phase III Acute heart failure; Chronic heart failure; Gestational diabetes; Heart failure; Renal failure
  • Phase II Decompensated heart failure

Most Recent Events

  • 14 Nov 2019 Boehringer Ingelheim and Eli Lilly files sNDA for adjunctive therapy treatment of patients with Type 1 diabetes mellitus in USA prior to November 2019
  • 14 Nov 2019 US FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) concludes that the benefits of empagliflozin 2.5mg do not outweigh the risks to support approval as an adjunct to insulin for adults with type 1 diabetes mellitus
  • 14 Nov 2019 Interim efficacy data from a phase III trial in Type I diabetes mellitus released by Boehringer Ingelheim and Eli Lilly
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top